Peter Hendricks Ph.D. – Is Psilocybin Helpful For People Who Abuse Cocaine?
Release Date: 06/30/2020
Psychedelics Today
Seeing What Is There is at the center of this conversation with journalist and author Erica Rex, who joins Joe Moore to discuss her book Seeing What Is There: My Search for Sanity in the Psychedelic Era. Rex brings an unusual mix of personal experience and scientific rigor. She came to psychedelic medicine after breast cancer, participation in Roland Griffiths’ clinical trial for cancer-related depression, and a long career in journalism covering science, nature, climate, and technology.
info_outlinePsychedelics Today
ALS and ketamine therapy are at the center of this conversation with psychiatrist and , who was diagnosed with in late 2023. Alpert is a Boston-area psychiatrist with experience in MDMA-assisted therapy research for PTSD and a private practice that includes . Alberding shares what it has been like to face a fatal neurodegenerative illness while working with ketamine in a structured clinical setting. Alberding explains that he was not looking for a casual psychedelic experience. He wanted help facing fear, grief, loss of function, and the reality of death. Over time, ketamine-assisted...
info_outlinePsychedelics Today
Dr. Esme Dark joins Kyle Buller for a conversation on psychedelic therapy, somatic psychotherapy, and shadow work. Based in Australia, Dark is a clinical psychologist, somatic psychotherapist, and psychedelic therapist. She shares her perspective on Australia’s authorized prescriber model, the role of psychotherapy in psychedelic care, and what it means to work with the body before, during, and after a psychedelic experience. The discussion stays practical. Dark draws on her work in research settings, including psilocybin-assisted psychotherapy for generalized anxiety disorder at Monash...
info_outlinePsychedelics Today
MAPS co-executive directors Betty Aldworth and Ismail Ali join Psychedelics Today to talk about leading one of the most visible organizations in the psychedelic field during a period of transition. The conversation covers their move into permanent leadership, how they work together, and how MAPS is thinking about research, education, policy, and movement strategy after a difficult period for the organization and the broader field.
info_outlinePsychedelics Today
Jen Davenport joins Psychedelics Today to interview co-founder Joe Moore about the growth of Psychedelics Today, the broader psychedelic ecosystem, and how professionals are beginning to engage with psychedelic ideas. Davenport is the founder of Iron Thread Partners and a graduate of the Vital psychedelic training program. Her work focuses on executive leadership, decision making, and organizational development. In this conversation she asks Moore about the evolution of Psychedelics Today and the changes he has witnessed across the psychedelic field over the past decade. Moore explains that...
info_outlinePsychedelics Today
& join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads , a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of , which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, . The conversation centers on veterans, the , and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC’s work on , including hosting events that bring...
info_outlinePsychedelics Today
Enamory is a clinical practice, training institute, and nonprofit research organization focused on psychedelic assisted couples therapy. In this episode, clinical psychologists Chandra Kian and Kayla Knopp discuss their work integrating ketamine assisted psychotherapy with evidence based couples therapy models. Both guests trained as academic researchers at the University of California San Diego Veterans Affairs system, where they worked on large scale couples based PTSD trials. They later co founded Enamory to continue clinical work, train therapists, and conduct research focused...
info_outlinePsychedelics Today
is a nonprofit that helps reduce the risks of psychedelic experiences through a free support line, coaching, education, and research. In this episode, Joshua White speaks with Psychedelics Today about why real-time support matters, what it takes to run a national hotline, and what Fireside learned after more than 30,000 conversations since launch. White shares how his background as a lawyer and his early hotline volunteering shaped Fireside’s model. He also describes how festival harm reduction work, including lessons from Zendo-style support spaces, revealed a major gap: people often...
info_outlinePsychedelics Today
Manvir Singh joins Psychedelics Today to unpack what shamanism means and why the term matters now. Singh is an anthropologist and author of Shamanism: The Timeless Religion. He argues that shamanism is not limited to “remote” societies or the past. Instead, it reliably reappears because it helps humans manage uncertainty, illness, and the unknown. This episode is relevant for the psychedelic community because “shaman” often gets used loosely, or avoided entirely. Singh offers a clear framework for talking about shamanic practice without leaning on romantic myths, drug-centered...
info_outlinePsychedelics Today
(Brighton, UK) joins Joe Moore for a grounded conversation on the boom in functional mushrooms and why the category may be moving too quickly. As the founder of , Oli works with consumers and brands to demystify functional mushrooms, with a focus on education, traceability, and realistic expectations. The conversation begins with a critique of wellness hype cycles. Oli explains how consumer desperation for help with anxiety, sleep, stress, and cognition can create an opening for a rapid wave of products that are not always grounded in careful sourcing or clear science. Using as a case...
info_outlineIn this episode, Joe speaks with Peter Hendricks, Ph.D. and Associate Professor at the University of Alabama, currently involved in researching the effects of psilocybin on people dealing with cocaine-related substance use disorder.
He discusses the details of the pilot trial (following the Johns Hopkins model, with music created by Bill Richards), some early findings and speculations, what music might work best for these sessions, how excited he is to bring these findings to the criminal justice system, and how religion and tribalism come into play when looking at what people get out of these psychedelic experiences.
Hendricks points out that while psilocybin is currently being researched as a treatment for tobacco use (by Matthew Johnson at Johns Hopkins) and alcohol use (by Michael Bogenschutz at NYU), this is the first large study with cocaine and could lead to the first medication for major stimulants. And while there have been many studies on psilocybin in general, they’ve rarely been focused on the people he’s working with, who are often poorer, less educated, often out of work, and usually struggling more than those typically involved in these studies. They also talk about what research of the past has given us data-wise, and how inspirational it has been to the work being done today.
Notable Quotes
“The participants in our trial- they haven’t read Michael Pollan’s book or others. They’re not in the know. I’ll have to explain to them what the drug is, and the common reaction is, ‘uhh, so you’re going to help me stop getting high by getting me high?’ and I’ll try to explain how the drug might differ from others, from more addictive drugs like cocaine. And as we know, it’s an ineffable experience- it’s a difficult experience to put to words…. I’m honored and I have admiration for our participants because they have the courage to dive into this study conducted at a University by people they’ve never met. It can be a very frightening experience and they say, ‘you know what, I’ve tried everything. At this point, I’m desperate, let’s give it a try.’ I probably couldn’t overstate how much courage it takes for them to do what they do. I don’t know that I could do it myself.”
“I think for most of the world’s fates, the tenants are that we’re all in this together, and we’re bound by love. And that really might be the message that most people get from psychedelics, but similar to religion, sometimes that message is perverted a bit and what you take from it is, ‘my in-group is what’s most important and I’m going to act to preserve my own tribe, even if it means treating others in an awful, inhumane way…’ Sometimes experiences that are really meant to foster a connection with everybody can go haywire and we have to be aware of that”
“One criticism of some of the studies conducted so far has been, how do we know that psilocybin might have these effects on a sample that isn’t all college-educated or doctorates or who are Professors at Universities who make more than 100,000 dollars per year and live comfortably? How do we know that this experience would have any meaning to somebody who’s making less than 10,000 per year, who has a fifth-grade education, who’s unemployed and homeless? I think in large part, this study might answer that question. If we find an effect, then we can say it appears to also have an effect among those who look different and whose life circumstances are much different than some of the earlier participants.”
Links
Support the show
- Patreon
- Leave us a review on Facebook or iTunes
- Share us with your friends
- Join our Facebook group - Psychedelics Today group – Find the others and create community.
Navigating Psychedelics
About Peter Hendricks PhD
Dr. Hendricks received his doctorate in clinical psychology from the University of South Florida and completed a post-doctoral Fellowship in Drug Abuse Treatment and Services Research at the University of California, San Francisco. His research centers on the development of novel and potentially more effective treatments for substance dependence, with specific areas of focus on tobacco, cocaine, and polysubstance dependence in vulnerable populations.



